nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

13.05.2016 | Letter to the Editor

Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?

verfasst von: Nuggehally R. Srinivas

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Excerpt

Fox et al. report an interesting pharmacokinetic/pharmacodynamic study of tariquidar, a potent Pgp inhibitor, in combination with three cytotoxic drugs agents namely docetaxel, vinorelbine, and doxorubicin [1]. The functional tracking of the ability of tariquidar to block Pgp efflux was monitored using rhodamine assay in the PBMCs prepared from the blood samples of patients, and the pharmacodynamic activity was measured by ^99mTc-sestamibi scintigraphy imaging in tumors [1]. …

Fox E, Widemann BC, Pastakia D et al (2015) Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol 76:1273–1283CrossRefPubMed

Bruno R, Sanderink GJ (1993) Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv 17:305–313PubMed

Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99–114CrossRefPubMed

van Zuylen L, Verweij J, Nooter K et al (2000) Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6:2598–2603PubMed

Kelly RJ, Draper D, Chen CC et al (2011) A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17:569–580CrossRefPubMed

Levêque D, Jehl F (1996) Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 31:184–197CrossRefPubMed

Wargin WA, Lucas VS (1994) The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol 21(5 Suppl 10):21–27PubMed

Levêque D, Merle-Melet M, Bresler L et al (1993) Biliary elimination and pharmacokinetics of vinorelbine in micropigs. Cancer Chemother Pharmacol 32:487–490CrossRefPubMed

Abraham J, Edgerly M, Wilson R et al (2009) A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 15:3574–3582CrossRefPubMed

10.

Mross K, Mayer U, Langenbuch T, Hamm K, Burk K, Hossfeld D (1990) Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients. Eur J Cancer 26:1156–1162CrossRefPubMed

11.

Ballet F, Vrignaud P, Robert J, Rey C, Poupon R (1987) Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver. Cancer Chemother Pharmacol 19:240–245CrossRefPubMed

12.

Camaggi CM, Strocchi E, Comparsi R, Testoni F, Angelelli B, Pannuti F (1986) Biliary excretion and pharmacokinetics of 4’epidoxorubicin (epirubicin) in advanced cancer patients. Cancer Chemother Pharmacol 18:47–50CrossRefPubMed

13.

Asakura E, Nakayama H, Sugie M et al (2004) Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol 484:333–339CrossRefPubMed

Titel: Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?
verfasst von: Nuggehally R. Srinivas
Publikationsdatum: 13.05.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3044-4

Neu im Fachgebiet Onkologie

10.04.2024 | PSA-Screening | Nachrichten

Springer Medizin

Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?

Excerpt

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience

A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma

Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors

Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study

Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie